Exagen Net Worth
Exagen Net Worth Breakdown | XGN |
Exagen Net Worth Analysis
Exagen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Exagen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Exagen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Exagen's net worth analysis. One common approach is to calculate Exagen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Exagen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Exagen's net worth. This approach calculates the present value of Exagen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Exagen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Exagen's net worth. This involves comparing Exagen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Exagen's net worth relative to its peers.
Enterprise Value |
|
To determine if Exagen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exagen's net worth research are outlined below:
| Exagen Inc is way too risky over 90 days horizon | |
| Exagen Inc appears to be risky and price may revert if volatility continues | |
| Exagen Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 52.55 M. Reported Net Loss for the year was (23.69 M) with profit before taxes, overhead, and interest of 21.35 M. | |
| Exagen Inc has about 76.39 M in cash with (14.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: Exagen CEO, President Director Acquires 7.7 percent More Stock |
Exagen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exagen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exagen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Exagen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exagen Inc backward and forwards among themselves. Exagen's institutional investor refers to the entity that pools money to purchase Exagen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kennedy Capital Management Inc | 2024-06-30 | 76.5 K | Palumbo Wealth Management Llc | 2024-09-30 | 76.4 K | Penbrook Management Llc | 2024-09-30 | 63 K | Ubs Group Ag | 2024-06-30 | 62.5 K | Blackrock Inc | 2024-06-30 | 43.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 29.8 K | State Street Corp | 2024-06-30 | 27.7 K | Citadel Advisors Llc | 2024-06-30 | 25.4 K | Prudential Financial Inc | 2024-09-30 | 21.8 K | Rtw Investments, Llc | 2024-06-30 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 964.8 K |
Follow Exagen's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 69.14 M.Market Cap |
|
Project Exagen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (1.04) | (1.10) |
When accessing Exagen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Exagen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exagen's profitability and make more informed investment decisions.
Evaluate Exagen's management efficiency
Exagen Inc has Return on Asset of (0.1741) % which means that on every $100 spent on assets, it lost $0.1741. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6997) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Exagen's Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Intangible Assets is likely to grow to about 6.6 M, while Total Assets are likely to drop about 54.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.28 | 1.35 | |
| Tangible Book Value Per Share | 1.28 | 1.35 | |
| Enterprise Value Over EBITDA | (1.17) | (1.23) | |
| Price Book Value Ratio | 1.55 | 1.18 | |
| Enterprise Value Multiple | (1.17) | (1.23) | |
| Price Fair Value | 1.55 | 1.18 | |
| Enterprise Value | 22.4 M | 27.9 M |
At Exagen Inc, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 1.2674 | Revenue 56.7 M | Quarterly Revenue Growth 0.066 | Revenue Per Share 3.163 | Return On Equity (0.70) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exagen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Birk Brian over three weeks ago Acquisition by Birk Brian of 9000 shares of Exagen subject to Rule 16b-3 | ||
Hunt Holdings Limited Partnership over two months ago Disposition of 30000 shares by Hunt Holdings Limited Partnership of Exagen at 16.133 subject to Rule 16b-3 | ||
Black Jeffrey G. over two months ago Acquisition by Black Jeffrey G. of 225000 shares of Exagen subject to Rule 16b-3 | ||
Stokes Frank over three months ago Insider Trading | ||
Adawi Kamal over six months ago Disposition of 9297 shares by Adawi Kamal of Exagen at 1.9089 subject to Rule 16b-3 | ||
Adawi Kamal over six months ago Disposition of 3487 shares by Adawi Kamal of Exagen at 1.9099 subject to Rule 16b-3 | ||
John Aballi over six months ago Acquisition by John Aballi of 175000 shares of Exagen subject to Rule 16b-3 | ||
Tullis James L L over a year ago Exagen exotic insider transaction detected | ||
Tullis James L L over a year ago Purchase by Tullis James L L of 167 shares of Exagen |
Exagen Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 5th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 14th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Exagen Earnings per Share Projection vs Actual
Exagen Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Debra Zack | Chief Officer | Profile | |
| John Wegener | Senior Marketing | Profile | |
| Ryan Douglas | Investors Officer | Profile | |
| Mark Hazeltine | Chief Officer | Profile | |
| MingChou Lee | Chief Officer | Profile |
Already Invested in Exagen Inc?
The danger of trading Exagen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exagen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exagen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exagen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.